MA29267B1 - Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension. - Google Patents

Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension.

Info

Publication number
MA29267B1
MA29267B1 MA30163A MA30163A MA29267B1 MA 29267 B1 MA29267 B1 MA 29267B1 MA 30163 A MA30163 A MA 30163A MA 30163 A MA30163 A MA 30163A MA 29267 B1 MA29267 B1 MA 29267B1
Authority
MA
Morocco
Prior art keywords
diazabicyclo
inhibitors
renine
methylphenoxy
dimethylbenzyl
Prior art date
Application number
MA30163A
Other languages
English (en)
Inventor
Olivier Bezencon
Daniel Bur
Walter Fischli
Lubos Remen
Sylvia Richard-Bildstein
Thierry Sifferlen
Thomas Weller
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36263952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29267(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA29267B1 publication Critical patent/MA29267B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE UN NOUVEAU DÉRIVÉ 3,9-DIAZABICYCLO[3.3.1]NONÈNE REPRÉSENTÉ PAR LA FORMULE GÉNÉRALE (I), SES ÉNANTIOMÈRES ET LEUR UTILISATION COMME INGRÉDIENTS ACTIFS DANS LA PRÉPARATION DE COMPOSITIONS PHARMACEUTIQUES. L'INVENTION CONCERNE ÉGALEMENT DES ASPECTS ASSOCIÉS, Y COMPRIS DES COMPOSITIONS PHARMACEUTIQUES CONTENANT AU MOINS UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE GÉNÉRALE (I) OU (I') ET EN PARTICULIER LEUR UTILISATION COMME INHIBITEURS DE LA RÉNINE.
MA30163A 2005-01-28 2007-08-24 Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension. MA29267B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2005000842 2005-01-28

Publications (1)

Publication Number Publication Date
MA29267B1 true MA29267B1 (fr) 2008-02-01

Family

ID=36263952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30163A MA29267B1 (fr) 2005-01-28 2007-08-24 Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension.

Country Status (20)

Country Link
US (1) US7915259B2 (fr)
EP (1) EP1846407B1 (fr)
JP (1) JP4111533B1 (fr)
KR (1) KR100938364B1 (fr)
CN (1) CN101107248A (fr)
AR (1) AR052894A1 (fr)
AT (1) ATE514697T1 (fr)
AU (1) AU2006208992A1 (fr)
CA (1) CA2595986A1 (fr)
CR (1) CR9268A (fr)
ES (1) ES2367267T3 (fr)
IL (1) IL184885A0 (fr)
MA (1) MA29267B1 (fr)
MX (1) MX2007009004A (fr)
NI (1) NI200700189A (fr)
NO (1) NO20074303L (fr)
RU (1) RU2007132438A (fr)
TW (1) TW200637861A (fr)
WO (1) WO2006079988A1 (fr)
ZA (1) ZA200705752B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005276624B2 (en) * 2004-08-25 2011-09-29 Actelion Pharmaceuticals Ltd. Bicyclononene derivatives as renin inhibitors
CA2608212A1 (fr) * 2005-05-27 2006-12-07 Actelion Pharmaceuticals Ltd Nouveaux derives d'amide d'acide piperidine carboxylique
CN101379033A (zh) * 2006-02-02 2009-03-04 埃科特莱茵药品有限公司 新颖二级胺
WO2007102127A2 (fr) * 2006-03-08 2007-09-13 Actelion Pharmaceuticals Ltd Nouvelles amines
CL2007002689A1 (es) * 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2008088690A2 (fr) * 2007-01-12 2008-07-24 Merck & Co., Inc. Procédé de préparation de composés diazabicyclo[3.3.1]nonane
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
JP2010527942A (ja) 2007-05-24 2010-08-19 メルク フロスト カナダ リミテツド 新規類のレニン阻害剤
WO2009023964A1 (fr) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Inhibiteurs de la rénine
WO2009135299A1 (fr) 2008-05-05 2009-11-12 Merck Frosst Canada Ltd. Dérivés de pipéridine substitués en 3,4 utilisés en tant qu'inhibiteurs de la rénine
RU2704112C2 (ru) 2013-10-25 2019-10-24 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0863875T3 (da) * 1995-09-07 2003-12-01 Hoffmann La Roche Hidtil ukendte 4-(oxyalkoxyphenyl)-3-oxy-piperiner til behandling af hjerte- og nyrelidelser
MXPA04010608A (es) * 2002-04-29 2004-12-13 Actelion Pharmaceuticals Ltd Derivados de 7-aril-3,9-diazabiciclo(3.3.1)non-6-eno y sus usos como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales.
WO2004096804A1 (fr) * 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Derives de diazabicyclononene et de tetrahydropyridine utilises comme inhibiteurs de la renine
BRPI0409882A (pt) * 2003-05-02 2006-05-23 Actelion Pharmaceuticals Ltd compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
US20060223795A1 (en) * 2003-05-02 2006-10-05 Oliver Bezencon Novel diazabicyclononene derivatives
WO2004105762A1 (fr) 2003-05-30 2004-12-09 Actelion Pharmaceuticals Ltd Utilisation medicale de derives de diazabicyclononene utilises comme inhibiteurs des proteases aspartiques parasites

Also Published As

Publication number Publication date
RU2007132438A (ru) 2009-03-10
IL184885A0 (en) 2007-12-03
CA2595986A1 (fr) 2006-08-03
AU2006208992A1 (en) 2006-08-03
EP1846407A1 (fr) 2007-10-24
NI200700189A (es) 2008-04-24
US7915259B2 (en) 2011-03-29
NO20074303L (no) 2007-08-22
KR100938364B1 (ko) 2010-01-22
MX2007009004A (es) 2007-09-14
US20080161313A1 (en) 2008-07-03
CN101107248A (zh) 2008-01-16
CR9268A (es) 2007-10-23
AR052894A1 (es) 2007-04-11
EP1846407B1 (fr) 2011-06-29
WO2006079988A1 (fr) 2006-08-03
ES2367267T3 (es) 2011-10-31
JP2008528478A (ja) 2008-07-31
JP4111533B1 (ja) 2008-07-02
ATE514697T1 (de) 2011-07-15
TW200637861A (en) 2006-11-01
ZA200705752B (en) 2009-02-25
KR20080001707A (ko) 2008-01-03

Similar Documents

Publication Publication Date Title
MA29267B1 (fr) Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension.
AU2003243836B2 (en) 8-hydroxy quinoline derivatives
MA33772B1 (fr) Dérivés d'acide carboxylique cyclique substitué par acylamino et leur utilisation en tant qu'agents pharmaceutiques
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
MA65277B1 (fr) Inhibiteurs de l'inflammasome nlrp3
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA33768B1 (fr) Triazolopyridines
MA30296B1 (fr) Nouvelles amines
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
TNSN04137A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
CA2367017A1 (fr) Inhibiteurs de l'enzyme impdh
MA29925B1 (fr) Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
TNSN07248A1 (fr) Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
NO20024521L (no) Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
MA30406B1 (fr) Nouveaux composes
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase